RxDoctor Payments Data

Mallory Wipf, PA

Physician Assistant · Rapid City, SDNPI 1417405416

Payments from drug & device makers

$1,502in general payments, 2019–2025

Across 70 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$449
  • Sanofi$263
  • Sanofi-aventis U.S. LLC$160
  • GSK$138
  • Takeda Pharmaceuticals U.S.A., Inc.$98
  • CSL Behring$86
  • plus $308 from 8 others

What the payments were for

  • Food & beverage$1,33789%
  • Education$16511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,502 in reported general payments places this provider in the 80th percentile of 548 physician assistant providers in South Dakota.

See all physician assistant providers in South Dakota

Medicare billing

Part B allowed, 2024
$53,064
Medicare patients
494
Services billed
1,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter394$389,255
Aralast NpAlpha-1-Proteinase Inhibitor17$168,694
Spiriva RespimatTiotropium Bromide122$113,028
NucalaMepolizumab16$87,825
Breztri AerosphereBudesonide/Glycopyr/Formoterol88$84,179
Stiolto RespimatTiotropium Br/Olodaterol Hcl95$73,475
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr106$68,796
Breo ElliptaFluticasone/Vilanterol72$48,601
DuleraMometasone/Formoterol64$30,494
Advair HfaFluticasone Propion/Salmeterol43$24,265
Albuterol Sulfate HfaAlbuterol Sulfate437$17,856
SymbicortBudesonide/Formoterol Fumarate48$17,409
Fluticasone-SalmeterolFluticasone Propion/Salmeterol112$15,756
Arnuity ElliptaFluticasone Furoate17$9,888
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate31$9,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$138$607,662616 claims
AstraZenecaBreztri Aerosphere, Symbicort$449$101,588136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 548 physician assistant providers in South Dakota.

Other physician assistant in Rapid City

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →